Booster shot
11 September 2017
Email
Share
Installing former Lundbeck boss Kare Schultz as CEO has given the Israeli drugmaker’s shares a shot in the arm. The new boss now needs to cut costs, and manage the group’s $35 bln debt pile. That’s hard given Teva’s challenges, and a tough market for generic drugs.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.